Search

Displaying results 4271 - 4280 of 10000 in total
  1. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099 … Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout

    Synonyms: L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T 676>S,
  2. Drug

    Hepatitis A Vaccine

    go.drugbank.com/drugs/DB10989
    ApprovedInvestigational

    [A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries.[L13392] … [A199182] Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection

    Categories: Complex MixturesProducts: AVAXIM 80 U PEDIATRIC, VAQTA VACCINE 25 u/0.5 ml
  3. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib]. … Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.

  4. Drug

    L-tartaric acid

    go.drugbank.com/drugs/DB09459
    Approved

    Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics … , and is a dihydroxyl derivative of succinic acid.

    Mixtures: U-Lite Effervescent Granules
  5. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … This approval is based on the favorable results from the pivotal phase 2 PHYOX<sup>TM</sup>2 and interim data from the ongoing phase 3 PHYOX<sup>TM</sup>3 clinical trials.[L48325]

  6. Drug

    Polysorbate 60

    go.drugbank.com/drugs/DB14153
    Investigational

    Mixtures: Medi SM 24K Gold Hydrogel Peptide Mask Pack
  7. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18. … [A235720] Although aducanumab's approval represents the first drug treatment for Alzheimer's disease, the approval is conditional on further results.

  8. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    Fulzerasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor. … Fulzerasib is under investigation in clinical trial NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-

  9. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.

  10. Drug

    Biapenem

    go.drugbank.com/drugs/DB13028
    Investigational

    It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use